Cambridge Biotherapies™, founded in 2016 by Daniel A. Brenner, M.D., was born out of a desire to help people who have tried traditional psychiatric treatments, such as medication and psychotherapy, with limited success.
Ketamine infusion therapy is a remarkably safe and effective treatment for depression and anxiety, offering rapid relief for patients who have not responded to traditional medications or therapies. The efficacy of ketamine for treatment-resistant depression is approximately 80%, matching that of ECT.
Ketamine is a dissociative anesthetic and is administered intravenously in a controlled environment, often as a series of 6 to 8 infusions over two to four weeks. It works by modulating glutamate receptors in the brain, leading to the release of neurotrophic factors that promote neural connections and neuroplasticity.
Numerous studies have shown that ketamine can produce significant and rapid improvements in depressive symptoms, including suicidal ideation and the impulse to self-harm, often within hours or days of treatment.
Ketamine has also demonstrated positive outcomes for anxiety disorders, including post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and social anxiety disorder (SAD).
We conduct careful and thorough evaluations with each patient. We are here to collaborate with you in any way that you or your patient feel would be helpful. We also conduct regular follow-ups and provide ongoing support to optimize treatment outcomes.
You can read more about clinical research on Ketamine here.
Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression and anxiety that uses magnetic fields to stimulate specific regions of the brain associated with mood regulation. Treatment is done once a day (for insurance-covered, standard TMS) and up to 10 times per day over 5 days for accelerated or SNT (SAINT) TMS.
TMS works by delivering focused magnetic pulses to the prefrontal cortex, stimulating neural activity and promoting the release of neurotransmitters like serotonin, norepinephrine, and dopamine.
Extensive research demonstrates that TMS is an effective option for treatment-resistant depression, providing significant symptom relief and improved quality of life. It has also been proven to reduce anxiety symptoms. Efficacy for traditional TMS for treatment-resistant depression is approximately 65%, while the efficacy of accelerated or SNT TMS is approximately 90%
TMS is generally well-tolerated and has a favorable safety profile. It has no systemic side effects and does not require anesthesia. The most common side effects are scalp discomfort or headache, which can be managed with over-the-counter pain relievers.
We conduct a thorough evaluation of each patient's history and symptoms before deciding if TMS is a suitable option. We monitor treatment on a daily basis to help optimize outcomes and ensure patient safety.
You can read more about clinical research on TMS here.
Ketamine-assisted psychotherapy combines the therapeutic effects of ketamine with the supportive framework of structured psychotherapy.
During ketamine-assisted psychotherapy sessions, a patient receives a subanesthetic dose of ketamine in a controlled setting, followed by therapeutic dialogue and processing with an experienced therapist trained in this modality. The integration of medication and therapy significantly enhances the therapeutic benefits of ketamine.
Studies have shown that ketamine-assisted psychotherapy can lead to sustained improvements in depressive and anxiety symptoms, providing relief for patients who have not responded to traditional treatments. The combination of pharmacological and psychological elements can create a synergistic effect, resulting in long-term positive outcomes.
Ketamine-assisted psychotherapy is generally considered safe when administered by trained professionals in a friendly and relaxing environment. Side effects are typically mild and transient, including dissociation, nausea, and increased blood pressure. Proper screening and monitoring protocols ensure patient safety throughout the treatment process.
Medical providers and psychotherapists considering ketamine-assisted psychotherapy for their patients should collaborate with our multidisciplinary team comprising psychiatrists and psychotherapists who are carefully trained and experienced in this modality. Before beginning KAP, we conduct a comprehensive evaluation to determine each patient’s suitability for this form of treatment. We take time to establish treatment goals, collaborate with outside treaters, and carefully prepare the patients so they can get the most out of this remarkable modality. We communicate regularly with outside providers to optimize the therapeutic benefits.
You can read more about clinical research on KAP here.